The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats.
Betty Tyler; Scott Wadsworth; Violette Recinos; Vivek Mehta; Ananth Vellimana; Khan Li; Joel Rosenblatt; Hiep Do; Gary L Gallia; I-Mei Siu; et al. (Profiled Authors: Betty Tyler; Gary Gallia; Michelle Rudek-Renaut; Henry Brem; Ming Zhao; I-Mei Siu)
Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA. firstname.lastname@example.org
Rapamycin, an anti-proliferative agent, is effective in the treatment of renal cell carcinoma and recurrent breast cancers. We proposed that this potent mammalian target of rapamycin inhibitor may be useful for the treatment of gliomas as well. We examined the cytotoxicity of rapamycin against a rodent glioma cell line, determined the toxicity of rapamycin when delivered intracranially, and investigated the efficacy of local delivery of rapamycin for the treatment of experimental malignant glioma in vivo. We also examined the dose-dependent efficacy of rapamycin and the effect when locally delivered rapamycin was combined with radiation therapy. Rapamycin was cytotoxic to 9L cells, causing 34% growth inhibition at a concentration of 0.01 µg/mL. No in vivo toxicity was observed when rapamycin was incorporated into biodegradable caprolactone-glycolide (35:65) polymer beads at 0.3%, 3%, and 30% loading doses and implanted intracranially. Three separate efficacy studies were performed to test the reproducibility of the effect of the rapamycin beads as well as the validity of this treatment approach. Animals treated with the highest dose of rapamycin beads tested (30%) consistently demonstrated significantly longer survival durations than the control and placebo groups. All dose-escalating rapamycin bead treatment groups (0.3%, 3% and 30%), treated both concurrently with tumor and in a delayed manner after tumor placement, experienced a significant increase in survival, compared with controls. Radiation therapy in addition to the simultaneous treatment with 30% rapamycin beads led to significantly longer survival duration than either therapy alone. These results suggest that the local delivery of rapamycin for the treatment of gliomas should be further investigated.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Federico G Legnani; Gustavo Pradilla; Quoc-Anh Thai; Alessandro Fiorindi; Pablo F Recinos; Betty M Tyler; Sergio M Gaini; Francesco DiMeco; Henry Brem; Alessandro OliviJournal of neuro-oncology 2006;77(3):225-32.
Maciej S Lesniak; Urvashi Upadhyay; Rory Goodwin; Betty Tyler; Henry BremAnticancer research 2005;25(6B):3825-31.
Violette Renard Recinos; Kimon Bekelis; Shira G Ziegler; Ditty Vick; Samuel Hertig; Betty M Tyler; Khan W Li; Thomas Kosztowski; Federico G Legnani; Henry Brem; et al.Journal of neuro-oncology 2010;97(1):1-10.
Appears in this Publication
Author of this Publication